RIBOXIN AMPOULES 2% 5ML

Packaging

10 vials of 5 ml.

Mechanism of action

Riboxin Bufus is a derivative (nucleoside) purine - the precursor of adenosine triphosphate (ATP). It belongs to the group of drugs that stimulate metabolic processes. It has antihypoxic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the effects of intraoperative renal ischemia. He is directly involved in glucose metabolism and contributes to the activation of metabolism in hypoxic conditions and in the absence of ATP.
It activates the metabolism of pyruvic acid, which is necessary for the normal process of tissue respiration, and also contributes to the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into the cells, it has a positive effect on metabolic processes in the myocardium - it increases the force of contractions of the heart and contributes to a more complete relaxation of the myocardium in diastole, as a result of which the stroke volume increases.The mechanism of antiarrhythmic action is not completely clear.
Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and gastrointestinal mucosa).

Comprehensive treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides, against the background of myocardial dystrophy after infectious diseases. Liver diseases (hepatitis, cirrhosis, fatty degeneration), urokoproporfiriya. Operations on an isolated kidney (as a means of pharmacological protection when blood circulation is turned off).

Contraindications

Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age up to 18 years (efficacy and safety have not been established).
Use with caution in renal failure.

Pregnancy and Breastfeeding

Contraindicated in pregnancy and lactation.

Dosage and administration

The drug is administered intravenously in a stream slowly or dropwise (40–60 drops in 1 minute). Treatment begins with the introduction of 200 mg (10 ml of 2% solution) 1 time per day, then, with good endurance, the dose is increased to 400 mg (20 ml of 2% solution) 1-2 times a day. Duration of treatment is 10–15 days.
Jet injection of the drug is possible in acute cardiac arrhythmias in a single dose of 200–400 mg (10–20 ml of a 2% solution).
For pharmacological protection of ischemic kidneys, Riboxin is administered intravenously in a single dose of 1200 mg (60 ml of a 2% solution) 5–15 minutes before clamping the renal artery, and then another 800 mg (40 ml of a 2% solution) immediately after the restoration of blood circulation.
When drip into a vein, a 2% solution of the drug is diluted in 5% dextrose solution (glucose) or an isotonic solution of sodium chloride (up to 250 ml).

Adverse reactions

Allergic reactions: skin itch, flushing of the skin, urticaria (the drug should be discontinued).
Seldom: increased concentration of uric acid in the blood, exacerbation of gout (with prolonged use).

Special notes

Riboxin is not used for emergency correction of disorders of the heart.

Drug Interactions

When used as part of complex therapy, Riboxin contributes to increasing the effectiveness of antiarrhythmic, antianginal and inotropic drugs.

Storage conditions

Store in a dark place at a temperature of from 15 to 25 ° C.

3 years.